Single- or dual-medication regimens
Single- or dual-medication regimens has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Aug 3, 2026: “Secondary prevention of myocardial infarction in people with dementia: a multi-jurisdictional retrospective cohort study in Asia, Europe and the USA”.
1 paper studies it1 findingUpdated
“all the remaining single- or dual-medication regimens were associated with higher risks of all-cause mortality”
- 1 lab in 1 country
- Funder: Department of Health and Human Services, State Government of Victoria
- 1 of 1 finding with company ties
- Humans1
What is Single- or dual-medication regimens linked with?
1Studies link Single- or dual-medication regimens with 1 measure, most often mortality (1 study).
Mortality
upin humans1
1 study
Mortality
upin humans1
Single- or dual-medication regimens are linked with a higher risk of mortality in humans.
“all the remaining single- or dual-medication regimens were associated with higher risks of all-cause mortality”
Humansexcluding the statin plus RASI without beta-blocker and the RASI plus beta-blocker without statin regimens, in people with dementia
Age and ageing
Latest
1 paper in 12 monthsAge and Ageing
Secondary prevention of myocardial infarction in people with dementia: a multi-jurisdictional retrospective cohort study in Asia, Europe and the USA
Cohort study of 260,360 peopleMyocardial infarction